Myeloproliferative Neoplasms
📧 Sign up to get email alerts when something new happens for Myeloproliferative Neoplasms.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-11-01Clinical Trial Update: Aquagenic Pruritus in Myeloproliferative Neoplasms
A completed clinical trial investigating aquagenic pruritus in patients with myeloproliferative neoplasms.
-
CLINICAL_TRIALS research · 2024-10-18Clinical Trial Update: Prevalence and Risk Factors of Pulmonary Hypertension in Patients with Myeloproliferative Neoplasms in Assiut University Hospital.
An observational study planned to determine prevalence and risk factors of pulmonary hypertension in patients with myeloproliferative neopla…
-
CLINICAL_TRIALS trial_result · 2024-10-15Clinical Trial Update: Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies [Phase 2]
Phase 2 trial evaluating post-transplantation bendamustine and cyclophosphamide in refractory myeloid malignancies has completed.
-
CLINICAL_TRIALS research · 2024-08-14Clinical Trial Update: Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)
Clinical trial evaluating the prognostic impact of decreased serum beta2 microglobulin in the first year of follow-up for myeloproliferative…
-
CLINICAL_TRIALS research · 2024-08-01Clinical Trial Update: Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen [Phase 2]
Phase 2 clinical trial evaluating sorafenib as relapse prophylaxis after hematopoietic cell transplantation using the PTBCy regimen; the stu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-07-23Clinical Trial Update: Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression [Phase 3]
Phase 3 trial evaluating haploidentical allogeneic peripheral blood transplantation with analysis of checkpoint immune regulator expression;…
-
CLINICAL_TRIALS research · 2024-07-01Clinical Trial Update: Characterization of Myeloproliferative Neoplasia With a Mutated IDH, SRSF2 or SF3B1 Allele (CARPEDIEM)
This clinical trial update describes the CARPEDIEM study characterizing myeloproliferative neoplasms with mutated IDH, SRSF2, or SF3B1. The …
-
CLINICAL_TRIALS research · 2024-07-01Clinical Trial Update: Diagnostic Characterization and Evolution of "Triple Negative" Thrombocytosis (CASTETTE)
This clinical trial update describes diagnostic characterization and evolution of a 'Triple Negative' thrombocytosis phenotype within myelop…
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: BeFluBu vs FluBuRux Conditioning in Haploidentical HCT [Phase 2]
Phase 2 clinical trial comparing BeFluBu vs FluBuRux conditioning regimens in haploidentical stem cell transplantation is currently recruiti…
-
CLINICAL_TRIALS research · 2024-06-26Clinical Trial Update: Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy
Status update for an ongoing trial (Observatory of Patients With Myeloproliferative Neoplasm Treated With Anti-inflammatory Immunotherapy) e…
-
CLINICAL_TRIALS trial_result · 2024-05-29Clinical Trial Update: Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients [Phase 2]
Phase 2 feasibility study evaluating apixaban for thromboprophylaxis in patients with JAK2-positive myeloproliferative neoplasms (including …
-
CLINICAL_TRIALS trial_result · 2024-05-07Clinical Trial Update: Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) [Phase 2]
This Phase 2 clinical trial update reports on conditioning with benadamustine, fludarabine, and busulfan (FluBuBe) for recipients of haploid…
-
CLINICAL_TRIALS trial_result · 2024-05-01Clinical Trial Update: A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis [Phase 2]
Phase 2 study of INCB050465 in combination with ruxolitinib for myelofibrosis. The trial was terminated and results were posted in May 2024.
-
CLINICAL_TRIALS trial_result · 2023-11-21Clinical Trial Update: Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors [Phase 2]
Phase 2 trial evaluating pevonedistat in combination with azacitidine for patients with myelodysplastic syndromes or myeloproliferative neop…
-
CLINICAL_TRIALS trial_result · 2023-01-06Clinical Trial Update: Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) [Phase 1, Phase 2]
Open-label, dose-escalation study of pemigatinib in advanced malignancies (FIGHT-101) completed; results posted.
-
CLINICAL_TRIALS trial_result · 2022-12-16Clinical Trial Update: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation [Phase 3]
A Phase 3 randomized trial comparing Fludarabine and Busulfan versus Fludarabine, Busulfan plus Total Body Irradiation in patients with myel…
-
CLINICAL_TRIALS trial_result · 2022-04-06Clinical Trial Update: A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms [Phase 2]
Phase II study of SGI-110 in Philadelphia-negative myeloproliferative neoplasms completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) [Phase 2]
Phase 2 study comparing ruxolitinib to anagrelide in essential thrombocythemia patients resistant to or intolerant of hydroxyurea; the trial…
-
CLINICAL_TRIALS trial_result · 2021-08-30Clinical Trial Update: An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis [Phase 2]
Open-label Phase 2 trial of itacitinib in patients with myeloproliferative neoplasms has completed.
-
CLINICAL_TRIALS trial_result · 2021-07-02Clinical Trial Update: A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis [Phase 2]
Phase 2 trial evaluating itacitinib with low-dose ruxolitinib or itacitinib alone after ruxolitinib in myelofibrosis; trial completed with r…
-
CLINICAL_TRIALS trial_result · 2020-01-28Clinical Trial Update: Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) [Phase 2]
Phase 2 trial assessing ruxolitinib (INCB018424) in participants with primary myelofibrosis and related post-MPN myelofibrosis conditions ha…
-
CLINICAL_TRIALS trial_result · 2019-02-28Clinical Trial Update: Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML [Phase 1, Phase 2]
A trial evaluating the combination of ruxolitinib and decitabine in accelerated phase myeloproliferative neoplasms or post-MPN acute myeloid…
-
CLINICAL_TRIALS trial_result · 2018-10-24Clinical Trial Update: Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders [Phase 2]
Phase 2 clinical trial evaluating fludarabine phosphate and total body irradiation followed by donor peripheral stem cell transplant in myel…
-
CLINICAL_TRIALS trial_result · 2018-05-31Clinical Trial Update: Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) [Phase 2]
Phase 2 clinical trial evaluating clofarabine plus low-dose cytarabine in higher-risk myelodysplastic syndromes has completed and results we…
-
CLINICAL_TRIALS trial_result · 2018-04-17Clinical Trial Update: A Study in Myeloproliferative Disorders [Phase 1]
Phase 1 study in myeloproliferative neoplasms has completed, evaluating patients with essential thrombocythemia, polycythemia vera, and prim…